Company intelligence / Profile preview

Intrinsyx Bio

Sunnyvale, California, United Statesintrinsyxbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Intrinsyx Bio developed and commercialized proprietary endophyte-based products that improve crop nutrient uptake, enhance plant health, and increase yields while reducing the need for synthetic fertilizers. Their technology has been validated through extensive lab and field trials across more than 20 crops. The company was acquired by Syngenta in May 2025 to strengthen Syngenta’s position as a leader in agricultural biologicals and nutrient use efficiency solutions

Modalities: Microbial therapyLive biotherapeutic product therapyBiologicals
Industry: Non-Drug Biotech

Drug pipeline

2 assets

Juno

Commercial

1 more asset in the full pipeline.

Request access →

Partnerships

SyngentaSABIC

Beyond the preview

Go deeper on Intrinsyx Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intrinsyx Bio.

Explore the full profile